In this issue:
- Vedolizumab + thiopurines vs vedolizumab monotherapy in IBD
- Continuation of anti-TNF after 24 weeks of pregnancy
- Roadmap to optimal peri-operative care in IBD
- Endoscopic healing and relapse anti-TNF withdrawal in IBD
- Predictors of primary response to biologic treatment in IBD
- Treatment persistence with ustekinumab in CD and vedolizumab in UC
- Vedolizumab vs ustekinumab in CD after failure of TNF-α inhibitors
- Ustekinumab and vedolizumab in IBD patients with prior malignancy
- Science blog: Immunometabolism and IBD
Please login below to download this issue (PDF)